Showing posts with label Hemcon. Show all posts
Showing posts with label Hemcon. Show all posts

Thursday, June 7, 2012

HemCon Adds Barry Starkman as CEO


HemCon Medical Technologies, Inc., an industry leader in hemorrhage control technologies and developer of lyophilized (freeze-dried) human plasma for the U.S. Army, announced today the appointment of Barry Starkman as Chief Executive Officer. Starkman joins HemCon with more than 30 years of experience in biologics and medical technology manufacturing.
"As we reorganize and restructure with the objective of successfully exiting Chapter 11, Barry is an extremely important addition to the HemCon team. His leadership and expertise will prove valuable in realizing the full potential of our lyophilized plasma program (LyP program), and in developing the optimal strategy for the Medical Device division," said Bill Wiesmann, Chairman and Co-Founder of HemCon. "Barry rounds out our executive team, working with Nick Hart who will continue his role as President and CFO."
As Chief Executive Officer, Starkman's focus will be on the execution and delivery of the LyP program through Phase 2 clinical trials and planning and executing on facility expansion to allow HemCon to enter Phase 3 clinical trials for the LyP program. He will also review the Medical Device division fully to determine the optimal means by which this business can be developed and contribute towards HemCon's overall financial performance.
Starkman's experience spans pharmaceutical products, biotech, and medical devices, matching the commercial applications for HemCon's LyP Program and Medical Devices division. His background also includes manufacturing management in the areas of facilities design, cGMP manufacturing requirements and Lean 6 Sigma applications.
Prior to joining HemCon, Starkman served as Vice President of Operations at Promega, where he was responsible for global manufacturing, planning and logistics for the $300 million organization. Starkman had previously overseen the design, construction, start-up and operation of Genentech's $450 million state-of-the-art formulation, packaging and distribution facility in Portland, serving as General Manager. Earlier in his career, Starkman worked for 24 years for Merck taking on increasing responsibility which culminated at Director of Manufacturing within Vaccine Operations.
"I am thrilled to become part of the HemCon team and bring my leadership skills to a company with breakthrough innovation in the plasma world and a proven track record of efficacious and safe medical devices which give HemCon immense potential," said Barry Starkman. "I look forward to working with the team in a timely exit from Chapter 11 and then helping HemCon realize its potential as a highly successful and viable enterprise."
HemCon Medical Technologies, Inc. ( www.hemcon.com ), founded in 2001, develops, manufactures, and markets innovative technologies for rapid delivery of plasma and hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where rapid supply of plasma and control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.
SOURCE: HemCon Medical Technologies, Inc.

Tuesday, April 10, 2012

HemCon Medical Technologies, Inc. Files for Chapter 11


HemCon Medical Technologies, Inc. (“HemCon”) announced today that it filed a voluntary petition for Chapter 11 reorganization in U.S. Bankruptcy Court.
The filing comes following the U.S. Court of Appeals for the Federal Circuit (CAFC) en banc decision on March 15, 2012 which affirmed an award of $34.2 million in damages to Marine Polymer Technologies, Inc. in a patent infringement case initiated in 2006.
“Chapter 11 gives us the best opportunities to maximize the value of HemCon and to continue to conduct business operations while we restructure debt, costs and other obligations,” said Nick Hart, HemCon’s President and Chief Financial Officer. “In addition, HemCon is planning on filing a petition to request that the CAFC rehear its 5-5 decision on claim construction, in the patent infringement case.”
During the past year, HemCon reformulated its chitosan-derived product line, branded as HemCon® PRO products. The HemCon PRO chitosan-derived product line has been successfully introduced in the U.S. and is approved for European and Japanese distribution, allowing for uninterrupted supply of product. Similarly, HemCon will continue supporting the recently introduced GuardaCare®XR Surgical product, as well as all of its other product lines including HemCon Patch® PRO and ChitoGauze® PRO.
HemCon anticipates commencing Phase II clinical trials in June for its U.S. Army-funded Lyophilized Plasma product (LyP). The U.S. military believes that early administration of plasma has an important role in reducing battlefield mortality rates, and sees this program as a top research and development priority.
HemCon’s European subsidiary is not subject to the Chapter 11 proceedings and will continue to operate as previously, selling its oxidized cellulose-based products including GuardIVa® Antimicrobial Hemostatic IV Dressing, Synaero™ Hemostatic Gel, and the consumer products line.
HemCon Medical Technologies, Inc. ( www.hemcon.com ), founded in 2001, develops, manufactures, and markets innovative technologies that control bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.
SOURCE: HemCon Medical Technologies, Inc.

Thursday, October 27, 2011

A keratin biomaterial gel hemostat derived from human hair: evaluation in a rabbit model of lethal liver injury.

Abstract

Effective hemostatic dressings that are compatible with tissues are needed. Keratins are a class of biomaterials that can be derived by extraction of proteins from human hair. We have recently discovered that keratin biomaterials have hemostatic characteristics and hypothesize that a keratin hydrogel having the ability to absorb fluid and bind cells may be an effective hemostat. The goal of this study was to test a keratin hydrogel and evaluate it compared to current hemostats. Thirty-two New Zealand white rabbits received a lethal liver injury. Eight animals each were assigned to negative control, QuickClot, HemCon bandage, and keratin treatment groups. Vital stats and other data were recorded during surgery and all surviving animals were sacrificed after 72 h. Histology was conducted on all surviving animals. Twenty-four-hour survival rates were 0%, 62.5%, 62.5%, and 75% for the negative control, QuickClot, HemCon, and keratin groups, respectively. Other outcomes included blood loss, mean arterial pressure, heart rate, shock index, and liver histology. All of the hemostats were statistically better than the negative control group at late operative time points. The keratin group consistently performed as well as, or better than, the commercial hemostats. Histology showed an interesting healing response at the hemostat-liver interface in the keratin group.

Wednesday, January 26, 2011

Morgan out, Hart in as CEO at Portland-based HemCon Medical Technologies

John W. Morgan, the chief executive of Portland-based HemCon Medical Technologies since 2004, resigned Monday "to pursue other opportunities," the company said in a press release.
He has been replaced as CEO by Nick Hart, who has been the company's chief financial officer for the last two years.
HemCon, a privately held company that makes and sells bandages and dressings that promote coagulation and discourage infection, employs about 126 people in Portland, Ireland and the Czech Republic. The company doesn't disclose revenues.
The company's dressings are derived from chitosan, a component of shrimp shells. They have been widely used by the U.S. military and, the company says, are responsible for saving at least 100 lives. For the last several years, the company has pushed aggressively into civilian markets.
A federal jury in New Hampshire last spring awarded a $29.4 million judgment to HemCon rival Marine Polymer Technologies, which makes a biocompatible dressing made from algae and claimed HemCon had violated its patent. HemCon appealed that award and has been permitted to continue selling its products while the case proceeds.
HemCon Chairman William P. Wiesmann said Monday that the change was "a natural progression," as Morgan sought bigger challenges.
Wiesmann said annual sales had fallen off from a high of more than $72 million several years ago, but that he expects the company to be profitable again by the fourth quarter of this year.

Saturday, November 20, 2010

Appeals Court Stays Judgment in HemCon's Patent Infringement Case

PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies, Inc., announced today that the U.S. Court of Appeals for the Federal Circuit granted HemCon's motion to stay the injunction and final judgment (including the damages award) obtained against it in a patent infringement case brought by Marine Polymer Technologies, Inc. The stay halts any enforcement of the lower court’s injunction and damages award while HemCon attempts to have both overturned on appeal, a process expected to take on the order of 12 to 18 months to complete. As a result, HemCon can continue selling its chitosan-based wound care products and will not be required to pay financial damages during this appeal process.
"HemCon is extremely pleased that the appellate court agreed that HemCon could continue selling its product line during the pendency of the appeal. We will urge on appeal that the lower court decision finding infringement was incorrect, in part because the Marine Polymer patent is invalid when properly interpreted," said John W. Morgan, HemCon's President and Chief Executive Officer. "The stay is a victory for HemCon's customers, including military personnel whose lives are being saved by HemCon products, and hospital patients who benefit from reduced infection risk and better hemostasis."
The stay is the most recent decision in the patent infringement action instituted by Marine Polymer Technologies, Inc. "In imposing the stay, the Court of Appeals concluded that HemCon had shown a strong likelihood of succeeding on appeal, or at least a substantial case on the merits and that any potential harm weighed in HemCon’s favor," Morgan explained. "We believe the appeals court will ultimately agree with our conclusion that our products do not infringe the Marine Polymer patent. We look forward to further presenting our case to the Court.”
HemCon Medical Technologies, Inc. (www.hemcon.com) founded in 2001, develops, manufactures, and markets innovative technologies to control bleeding and infection resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.

Friday, September 24, 2010

ENTrigue sell Gell into ENT - with Hemcon help

SAN ANTONIO, Sept. 23 /PRNewswire/ -- ENTrigue Surgical, Inc. ("ENTrigue"), a San Antonio, Texas-based company that designs, develops, manufactures and distributes medical devices used for Ear, Nose and Throat surgical procedures, announced today the first clinical experience with its Ventera™ sinus dilation systems.  The Company also announced that it will launch its Synaero™ Hemostatic Gel at the American Academy of Otolaryngology Annual Symposium and Exhibition ("AAO Meeting") in Boston, Massachusetts, September 26-29, 2010 attended by ENT surgeons from around the world.
The Ventera™ sinus dilation systems include a single-use balloon delivered by one of several reusable instruments utilizing ENTrigue's proprietary SerpENT® articulating technology and does not require the use of a guide wire or cannula for delivering the balloon into various sinuses.  The initial clinical cases were performed by Dr. Amin Javer, a world renowned rhinologist and Director of the St. Paul's Sinus Center in Vancouver, Canada.  ENTrigue is in an early-launch phase with the Ventera™ systems in Canada and plans to launch the systems to various European markets over the next few months.  The Ventera™ technology is not presently available for sale in the United States.
Dr. Javer remarked, "The Ventera systems offer an elegant and intuitive approach to sinus dilation.  I am excited about the potential these systems offer as minimally invasive tools for managing sinus disease."  
The Company's new Synaero™ product is a hemostatic gel used to control mucosal bleeding related to sinus surgery and was co-developed with HemCon Medical Technologies Inc., a leading global developer and manufacturer of hemorrhage control products headquartered in Portland, Oregon.  The Synaero™ Hemostatic Gel, as well as the Ventera™ sinus dilation balloon and related instruments, will be on display at the ENTrigue booth at the AAO Meeting.  
ENTrigue also announced the addition of John T. Treace to its Board of Directors.  Treace is Sr. Vice President of Global Marketing and US Sales at Wright Medical Technology, Inc. in Arlington, Tennessee, and served as Director of Marketing for Medtronic ENT for several years prior to Wright.  He joins current Board members Fred Dinger, President & CEO; Donald Gonzales, M.D., Chief Medical Officer; Richard Emmitt of The Vertical Group; and Anthony Natale, M.D. of Prism VentureWorks

Saturday, September 18, 2010

HemCon Medical Technologies Will Appeal Patent Judgment

PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies, Inc., announced today that it will appeal a permanent injunction entered by a US District Court in New Hampshire based on a patent held by Marine Polymer Technologies, Inc. The injunction enjoins further manufacture, use and sale of HemCon’s HEMCON® BANDAGE, CHITOFLEX® DRESSINGS, HEMCON® DENTAL DRESSINGS and any other products which are no more than colorably different from those products. HemCon intends to file a motion for an emergency stay of the injunction during the pendency of the appeal."HemCon will urge on appeal that the Marine Polymer patent is not infringed and/or is invalid, and ask the appellate court to overturn or vacate the judgment. We firmly believe that the lower court made the wrong decision and we are hopeful that the Court of Appeals will correct this and find that HemCon’s products do not infringe the patent or that the patent is invalid,” said John W. Morgan, HemCon's President and Chief Executive Officer.
Marine Polymer sued HemCon in 2006, alleging that HemCon had violated its patent covering a biocompatible chitosan compound. Marine Polymer’s patent describes a chitosan compound that is derived from the sterile culturing of marine micro algae.
HemCon uses a chitosan compound to manufacture highly effective bandages that have been used in battlefield conditions by the U.S. military, among others. HemCon does not use chitosan that is derived from sterile culturing of micro algae, as described in the Marine Polymer patent.
HemCon has separately initiated a proceeding to reexamine the validity of the patent through the US Patent & Trademark Office. In 2009, HemCon filed a request with the Patent Office to reexamine, and possibly invalidate or limit, Marine Polymer’s patent in light of prior publications about chitosan. The Patent Office granted the Request for Reexamination in November 2009. On April 1, 2010, the Patent Office issued a first office action, rejecting all claims of Marine Polymer’s patent. Marine Polymer has filed a response canceling some patent claims and arguing that the remaining claims are valid as originally issued.

Tuesday, June 29, 2010

HemCon Medical Technologies Introduces GuardIVa™

PORTLAND, Ore., and DUBLIN, Ohio, June 23, 2010 — HemCon Medical Technologies Inc. today announced the launch of the HemCon© GuardIVa™ Antimicrobial Hemostatic IV Dressing, the only antimicrobial dressing containing both a hemostatic compound and the antiseptic agent chlorhexidine gluconate (CHG). The company also announced a five-year sole-source distribution agreement with Cardinal Health to provide the new dressing to hospitals and surgery centers in single sterile units and within Cardinal Health Presource® procedure packs.

Because of its proprietary hemostatic compound, GuardIVa can be used in the first 24 hours after placement of IV devices to control bleeding and provide immediate antimicrobial protection to the IV site. GuardIVa is also able to absorb up to 11 times its own weight in fluid, reducing the need for frequent dressing changes.

GuardIVa’s CHG base also provides more effective and sustained antimicrobial activity over a seven-day span than the silver base used in other antimicrobial dressings.1 The use of CHG-based dressings helps protect against micro-organisms such as Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-Resistant Staphylococcus epidermidis (MRSE).

“GuardIVa’s superior hemostatic and antimicrobial qualities reduce the need for frequent dressing changes and provide a complete and cost-effective solution to help drive patient safety and IV site infection management,” said John W. Morgan, CEO of HemCon Medical Technologies, Inc. “We’re excited to be able to partner with Cardinal Health to extend this complete IV site care solution to its customer base of infection specialists and health care professionals leading the charge for infection control.”

Central Venous Catheters (CVCs) and Peripherally Inserted Central Catheters (PICCs) are among the ideal applications for GuardIVa.

“We know there is a heightened focus on infection prevention, especially as it relates to catheter-related bloodstream infections,” said Debra Schotz, senior vice president of Patient Care at Cardinal Health. “By including GuardIVa in our portfolio in addition to our full line of Presource standard and custom kits, we’re helping our customers comply with recommendations from the Institute for Healthcare Improvement calling for maximal barrier protection and a kit or central line bundle to improve compliance for catheter insertion and maintenance procedures.” 2

For product information, Cardinal Health customers should contact their nursing products or Presource sales representative. Information is also available through Cardinal Health by calling Jaime Simon at (614) 553-4663 for single sterile use or Crystal Humphreys at (614) 553-5263 for in-kit use.


Monday, May 24, 2010

Hemostasis Blog Valued Resource!

The Medical Hemostat Blog has gained wide geographical and company interest. You are welcome to contact me at hemostatguy@gmail.com. I also have consulted with market research firms such as Frost and Sullivan amongst other research organisations.

While I address a need for comprehensive information regarding hemostasis, I am pleased to announce our top, google analytics identified company visitors:

  1. Johnson & Johnson
  2. CryoLife
  3. Baxter
  4. Trauma Cure
  5. Tyco
  6. Zymogenetics
  7. Medafor
  8. Hemcon
  9. King Pharmaceuticals
  10. Entegrion
  11. St. Jude
  12. Aventis Behring
I would appreciate any contributions readers care to send and am actively seeking projects in this field.
Thank You for following the Blog.
HG

Thursday, May 6, 2010

HemCon to ask court to reverse $29.4M patent award

An Oregon company plans to challenge a $29.4 million jury award to a Massachusetts company for patent infringement over a product derived from shrimp shells or algae that can be used to control bleeding. HemCon Medical Technologies Inc. of Portland says it makes a material called chitosan from shrimp shells while Marine Polymer Technologies in Danvers, Mass., makes it from algae. The chitosan is used in bandages to help control bleeding and infection from trauma or surgery and to treat battlefield wounds for the military. Last week, a U.S. District Court jury in Concord, N.H., ruled in favor of Marine Polymer in a patent infringement lawsuit it filed against Hemcon four years ago. Sergio Finkielsztein, president and CEO of Marine Polymer, praised the verdict and said the company will seek a permanent injunction against HemCon. "Our company was built on innovation, and new technologies we have developed since the early 90s and continue to develop to this day," Finkielszstein said. But John Morgan, president and CEO of HemCon, said the verdict would allow the patent to cover shrimp-based chitosan compounds that were publicly disclosed by others well before the Marine Polymer patent application was filed. "We believe the jury's decision is wrong and will ask the court to review and reverse it," Morgan said Wednesday. He also said the U.S. Patent Office granted a HemCon request for re-examination of the patent last November and the agency made an initial determination last month to reject Marine Polymer's claims. Morgan said the Patent Office indicated its willingness to allow the claims of the patent if Marine Polymer would limit them to algae. "There were broad claims in the patent that looked at all forms of materials," Morgan said. "But clearly the process and material employed by Marine Polymer is not what we used."

Tuesday, March 31, 2009

HemCon Patch

HemCon Medical Technologies offers a more flexible HemCon Patch designed for use for external, temporary control of bleeding during interventional and diagnostic cardiac catheterization, interventional radiology, electrophysiology and dialysis access procedures.

Offering diagnostic and interventional patients a quick, safe and comfortable post-procedural experience, the HemCon Patch delivers a flexible hemostatic solution where rapid arterial hemostasis is critically important to ensure quality care and safety. It stops bleeding and minimizes risk of artery damage. As one of the only hemostatic products to obtain an FDA antibacterial barrier claim, the HemCon Patch provides a barrier against a wide spectrum of micro-organisms, including methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis (VRE) and Acinetobacter baumannii. This barrier may help to reduce the risk of hospital-acquired infections for both patients and providers. The HemCon Patch is also suited for patients that take anticoagulant medications or suffer from clotting or bleeding disorders.

Tuesday, February 24, 2009

Hemcon Expands Hemostasis Line

Hemcon announced Tuesday that its flexible hemostatic dressing HemCon Patch is now available for clinical settings. The dressing can be used for external, temporary control of bleeding during interventional and diagnostic cardiac catheterization, interventional radiology, electrophysiology and dialysis access procedures. Portland-based HemCon said offering diagnostic and interventional patients a quick, safe and comfortable post-procedural experience, the HemCon Patch delivers a flexible hemostatic solution where rapid arterial hemostasis is critically important to ensure quality care and safety. It reliably and quickly stops bleeding, minimizes risk of artery damage and frees up medical personnel. As one of the only hemostatic products to obtain an FDA antibacterial barrier claim, the HemCon Patch provides a barrier against a wide spectrum of micro-organisms, including methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis (VRE) and Acinetobacter baumannii.

Thursday, August 28, 2008

HemCon Medical Technologies, Inc. and IT/Sligo Join Forces

PORTLAND, Ore. & SLIGO, Ireland--(BUSINESS WIRE)--HemCon Medical Technologies today announced an agreement with IT/Sligo (Institute of Technology Sligo, Ireland) to license the exclusive global rights to research, develop, manufacture and market a controlled release hydrogen peroxide technology that provides broad spectrum antibacterial and antiseptic properties.
This proprietary platform technology provides a full range of product solutions for the wound care, oral care and personal care markets ranging from antimicrobial professional products to personal hygiene solutions for consumers. The technology allows entry into major new market opportunities for HemCon Medical Technologies. Of particular significance the technology has shown good potential in early studies for the treatment of fungal nail infection. Fungal nail infection affects tens of millions of people in the U.S. and the global market size for its treatment products is approximately US$4 billion.
The platform technology releases hydrogen peroxide through a carefully controlled proprietary process allowing control of the dose and of the period of delivery of the produced hydrogen peroxide. The hydrogen peroxide at the required level is slowly released over a controlled time, providing a steady dose while ensuring that the levels produced are below those that could be harmful.
“The new licensing agreement with IT/Sligo is an exciting partnership for HemCon as we continue to grow and pioneer new products in wound care and healing,” said John W. Morgan, CEO of HemCon. “This particular technology will also expand our presence in key markets like fungal care. With more than 40 million Americans fighting fungal infections, it will be a valuable new tool for effective treatment.”
The agreement will allow HemCon the ability to directly commercialize or sub-license these technologies to key medical device and pharmaceutical partners globally.

Sunday, June 8, 2008

Comparison of Celox, Hemcon and Quikclot

Celox sent me this report comparing Hemcon and Z-medica with Celox HERE (its a verified safe Pdf download from adrive).
Given the positive results I was left wondering why this product was not the sole choice of the Military, in particular the US forces?
So I emailed Craig Hardy, CEO, MedTrade Products Ltd and asked him........

Me: According to the Jan. ’08 Portsmouth pdf study (comparing Celox with Hemcon and Z-medica’s, Quikclot) the results indicate Celox shows a 100% survival rate. Is this product currently undergoing any evaluation by the military?

Craig: Yes. Celox is used in some performance critical areas of the military and being evaluated in many others. Its an ongoing process.

Me: Given that Medtrade is a U.K. based company what (if any) impact has this had for the uptake of Celox by the U.S. military?

Craig: In the US, Celox is distributed to the Military through Sam Medical in Portland Oregon. The UK is a very close ally of the US. We have heard of no decisions made on the basis of location. However our head office location means we are not as politically connected as some competitors and I believe this may have a significant effect.

Wednesday, May 28, 2008

HemCon Medical Technologies Leverages Sangui Technology to Expand its Wound Care Products Line


PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies Inc. today announced it will use Witten, Germany-based SanguiBioTech GmbH’s ChitoSkin technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute care market.
Under the terms of the agreement, HemCon will leverage Sangui’s technology platform to enhance and expand its product offerings for surgical and wound care. HemCon developed the chitosan-based hemostatic HemCon® Bandages and ChitoFlex® dressings that are used by military and medical first responders as well as health care professionals around the globe.
“We explored a wide variety of technology platforms to add to our new surgical and wound care offerings and feel that the Sangui chitosan platform offers great opportunities to enhance our solutions,” said John W. Morgan, president and CEO of HemCon. “We’re committed to continuing our investment to develop new choices for medical professionals and consumers. This agreement is an important step forward in realizing the full potential of chitosan-based products.”
SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. Sangui BioTech International focuses on vascular and hemostasis products. The firm specializes in developing oxygen-carrying agents to treat blocked arteries, anemia or acute blood loss through SanguiBioTech GmbH.
“We are proud to enter into an agreement with HemCon and offer our chitosan platform to help innovate new surgical and wound care products,” said Sangui Managing Director Hubertus Schmelz. “There is definitely a demand for products that can adapt to specific medical needs, especially as it relates to wound care.”
HemCon retains exclusive worldwide market and distributing rights for products developed under this structured financial agreement. HemCon will submit developed products for U.S. approvals to the FDA, while Sangui will prepare documentation for registration in the European Union.

Wednesday, May 14, 2008

HemCon completes acquisition of Alltracel Pharmaceuticals

HemCon Medical Technologies Inc. said Wednesday it has completed the acquisition of Dublin, Ireland-based Alltracel Pharmaceuticals in a cash-for-stock deal.
The purchase occurred through Castlerise Investments Ltd., a newly formed wholly owned subsidiary of HemCon. Alltracel will operate as a wholly owned subsidiary of HemCon and maintain its headquarters in Dublin. Combined revenue is expected to exceed $100 million.
Alltracel licenses their proprietary technologies across a wide spectrum of industries in the wound care markets. In addition, Alltracel offers private-label oral care products licensed in Europe through the Butler and GUM brands. The acquisition expands distribution opportunities for HemCon's KytoStat Bandage and other products in Europe while also expanding Alltracel's oral care products and medical technologies in the United States.
"We look forward to combining our resources and continuing to innovate," said John W. Morgan, CEO of Portland-based HemCon, in a statement. "The acquisition further strengthens HemCon's ability to develop health care breakthroughs and life-saving technologies on a global scale."
HemCon develops and makes products that control bleeding and infection resulting from trauma or surgery.
The company's signature product is a bandage -- made from material extracted from shrimp shells called chitosan -- that bonds to severe wounds within minutes of being applied.
Source Portland Business Journal

Tuesday, May 13, 2008

U.S. Army Selects HemCon Medical Technologies as Sole Source Partner to Develop Lyophilized Human Plasma


The U.S. Army has selected HemCon Medical Technologies Inc. as the sole source to develop, test and secure FDA approval for a lyophilized (freeze-dried) human plasma (LHP) product and delivery system. The $15.4 million multi-year cooperative agreement will support the research and development of the new process. The project is expected to be complete in 2010.
The use of plasma as a resuscitation fluid, according to early U.S. Army studies, has shown to significantly reduce battlefield mortality. In many situations, use of fresh frozen human plasma is limited by storage requirements and the short shelf-life for thawed plasma. As a life-saving measure for coagulopathy, the US Army Medical Research and Materiel Command has identified the LHP initiative as a high priority. The new LHP product and delivery system will offer individual units of single source donor plasma that are safe and easy to carry, reconstitute and administer.
HemCon previously partnered with the U.S. Army to develop the HemCon® Bandage. Since 2003, HemCon has produced and distributed the HemCon Bandage and ChitoFlex® dressings for the U.S. Army and other military and civilian medical professionals. The chitosan-based hemostatic dressings, manufactured using a proprietary process, are currently included in every U.S. soldier’s battlefield first-aid kit. The success of the HemCon Bandage led to improved civilian patient care when the bandage moved to acute care facilities in 2007.
Leveraging a core competency in lyophilization, HemCon plans to do the same with its LHP initiative – improve battlefield and civilian care. Success of the LHP process on the battlefield could mean improved care for civilians. Responsible for more than 160,000 deaths annually, the National Trauma Institute reports that trauma is the leading cause of death in the U.S. for individuals ages one to 44. An LHP product and delivery system that is readily available at the point of care could significantly decrease mortality for these patients. Another advantage of LHP is the ability to reconstitute in less than 2 minutes; where waiting 20 minutes for fresh frozen plasma to thaw – may be the difference between life and death.
“This is a crucial initiative, and HemCon is honored to be the choice of the U.S. Army,” said John W. Morgan, president and CEO of HemCon. “Developing a lyophilized human plasma product and delivery system will be a significant evolution for battlefield and civilian trauma care. It’s also an important evolution for HemCon as we expand our presence in global health care markets. As the use of LHP carries into the civilian medical space, I believe we will see increased survival rates in patients treated at smaller hospitals and numerous trauma centers where currently, fresh frozen plasma is not readily available.”
Source BusinessWire

Wednesday, April 30, 2008

Who else is interested in Nanotech? ........Hemcon, Alltracel


HemCon's acquisition of Alltracel gives access to Alltracel's joint venture with Elmarco and its proprietary nanotechnology manufacturing process called Nanospider®. HemCon will seek to leverage this process to aggressively grow its market share in acute wound care products developed from chitosan.

Elmarco is a specialist R&D and manufacturing company that has developed, in conjunction with the Technical University of Liberic, a novel proprietary & patented process for spinning polymers into nano-scale fibres for a range of industrial, chemical, micro-electronic and bio-medical applications. This proprietary technology branded Nanospider", represents a major breakthrough in the mass production of nanofibre materials and is now deployed in a number of markets including medical products.
NANOPEUTICS headquartered in Liberic in the Czech Republic and operating internationally has been assigned the relevant woundcare and Nanospider(TM) intellectual property and patents and has already been in advanced discussions including successful product testing with a number of existing consumer and professional woundcare companies.